

JUN 23 2003

K031015

X. PREMARKET NOTIFICATION SUMMARY

Submitted by: Vitrolife Sweden AB
Mölnadalsvägen 30
SE-412 63 Gothenburg
SWEDEN

Contact Person: Ms. Nina Arvidsson
Vitrolife Sweden AB
Mölnadalsvägen 30
SE-412 63 Gothenburg
SWEDEN

Mr. Gary L. Yingling
Mr. Michael H. Hinckle
Kirkpatrick & Lockhart, LLP
1800 Massachusetts Avenue, NW
Washington, DC 20036-1800

Date Prepared: March 27, 2003

Trade Name: EmbryoGlue™

Common Name: Assisted Reproduction Media

Classification Name: Reproductive Media and Supplements
(21 C.F.R. § 884.6180)

Predicate Device: G-2™ version 3, supplemented with G-MM™

Description of the Device: Bicarbonate buffered medium containing
Hyaluronan and Recombinant Human Albumin.

Intended Use: Medium for *In Vitro* Fertilization Procedures

Indications for Use: Medium for embryo transfer

Technological Characteristics:

The EmbryoGlue™ device is a modification of G-2™ version 3, supplemented with G-MM™. The technological characteristics of EmbryoGlue are essentially similar to those of the predicate device. The EmbryoGlue contains Recombummin and is not intended to be supplemented with albumin prior to use. Other changes are the product packaging and the fact that EmbryoGlue contains a higher concentration of Hyaluronan. None of these differences raise new questions of safety or effectiveness.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUN 23 2003

Ms. Nina Arvidsson
Regulatory Affairs Officer
Vitrolife Sweden AB
Mölnadalsvägen 30
SE-412 63 Gothenburg
SWEDEN

Re: K031015
Trade/Device Name: EmbryoGlue™ Assisted
Reproduction Medium
Regulation Number: 21 CFR 884.6180
Regulation Name: Reproductive media
and supplements
Regulatory Class: II
Product Code: 85 MQL
Dated: March 27, 2003
Received: March 31, 2003

Dear Ms. Arvidsson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

XI. INDICATIONS FOR USE STATEMENT

510(k) Number: K 031015

Device Name: EmbryoGlue™
Assisted Reproduction Media

Indications For Use: Medium for embryo transfer

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use _____
(Per 21 C.F.R. § 801.109)

OR Over-the Counter Use _____

David G. Ferguson
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number K031015